USE OF CD90+ HUMAN AMNIOTIC EPITHELIAL CELLS IN TREATMENT OF GRAFT VERSUS HOST DISEASE
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Feb 6, 2025
app pub date -
Sep 30, 2021
filing date -
Sep 30, 2021
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
A method for treating a subject suffering from a graft versus host disease (GvHD) or with the risk of GvHD, comprising: selecting a CD90+hAEC cell population with a stronger immunoregulation capability as a primary therapeutic cell. Research on related action mechanisms finds that the stem cell pluripotent markers SSEA4, OCT4 and NANOG of CD90+hAECs are significantly higher than general hAECs, and have better immunomodulatory functions, and therefore, the CD90+hAECs cells are used as therapeutic means to obtain better clinical results.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully